NO954342D0 - Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav - Google Patents

Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Info

Publication number
NO954342D0
NO954342D0 NO954342A NO954342A NO954342D0 NO 954342 D0 NO954342 D0 NO 954342D0 NO 954342 A NO954342 A NO 954342A NO 954342 A NO954342 A NO 954342A NO 954342 D0 NO954342 D0 NO 954342D0
Authority
NO
Norway
Prior art keywords
processes
preparation
well
erythropoietin analog
analog mixtures
Prior art date
Application number
NO954342A
Other languages
English (en)
Other versions
NO954342L (no
Inventor
Gregory F Okasinski
Peter J Devries
Barry S Mellovitz
Joseph L Meuth
Verlyn G Schaefer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO954342L publication Critical patent/NO954342L/no
Publication of NO954342D0 publication Critical patent/NO954342D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO954342A 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav NO954342D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5507693A 1993-04-29 1993-04-29
PCT/US1994/004755 WO1994025055A1 (en) 1993-04-29 1994-04-29 Erythropoietin analog compositions and methods

Publications (2)

Publication Number Publication Date
NO954342L NO954342L (no) 1995-10-30
NO954342D0 true NO954342D0 (no) 1995-10-30

Family

ID=21995426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954342A NO954342D0 (no) 1993-04-29 1995-10-30 Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav

Country Status (13)

Country Link
US (1) US5888772A (no)
EP (1) EP0744953A4 (no)
JP (1) JPH08509614A (no)
KR (1) KR960701650A (no)
CN (1) CN1125401A (no)
AU (1) AU697453B2 (no)
BR (1) BR9406490A (no)
CA (1) CA2161651A1 (no)
CZ (1) CZ286046B6 (no)
FI (1) FI955128L (no)
HU (1) HUT73876A (no)
NO (1) NO954342D0 (no)
WO (1) WO1994025055A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
KR100400637B1 (ko) * 1996-02-06 2004-03-10 씨제이 주식회사 생물학적으로유용한펩타이드
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
EP1731174A3 (en) * 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
ATE339507T1 (de) 1998-06-15 2006-10-15 Gtc Biotherapeutics Inc Erythropoietin-analog-menschliches serum-albumin fusionsprotein
WO2000032772A2 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EE200300089A (et) * 2000-09-08 2005-02-15 Gryphon Therapeutics, Inc. Sünteetilised erütropoeesi stimuleerivad valgud, nende valmistamismeetodid ning kasutamine
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CA2521273A1 (en) * 2003-04-02 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
MX2008014744A (es) 2006-05-19 2009-02-10 Glycofi Inc Composiciones de eritrocpoyetina.
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
CN103113464B (zh) * 2007-07-02 2014-08-20 沈阳三生制药有限责任公司 天然人促红细胞生成素类似物
WO2009094202A1 (en) * 2008-01-22 2009-07-30 Warren Pharmaceuticals Inc. Method of treating cancer, neoplastic disorders, and symptoms thereof with compounds
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
US20130034875A1 (en) * 2009-10-01 2013-02-07 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
CN102205114B (zh) * 2011-04-29 2012-12-12 中国人民解放军第三军医大学 促红细胞生成素来源肽在制备治疗神经系统自身免疫性疾病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
AU6778594A (en) 1994-11-21
FI955128A7 (fi) 1995-10-27
FI955128A0 (fi) 1995-10-27
CZ284495A3 (en) 1996-02-14
CZ286046B6 (cs) 1999-12-15
EP0744953A4 (en) 1998-05-06
BR9406490A (pt) 1996-03-05
CA2161651A1 (en) 1994-11-10
KR960701650A (ko) 1996-03-28
EP0744953A1 (en) 1996-12-04
HU9503088D0 (en) 1995-12-28
JPH08509614A (ja) 1996-10-15
CN1125401A (zh) 1996-06-26
NO954342L (no) 1995-10-30
AU697453B2 (en) 1998-10-08
US5888772A (en) 1999-03-30
WO1994025055A1 (en) 1994-11-10
FI955128L (fi) 1995-10-27
HUT73876A (en) 1996-10-28

Similar Documents

Publication Publication Date Title
NO954342D0 (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
NO941104D0 (no) Asfaltblandinger, samt fremgangsmåte ved fremstilling derav
ES1026992Y (es) Barandilla, manija o analogo.
BR9400616A (pt) Processo para a preparação de 1,1,1,4,4,4-hexafluorbuteno-2
FR2709812B1 (fr) Procédé de combustion.
BR9400604A (pt) Processo para a preparação de 1,1,1,3,3-pentafluorpropano
NO900741D0 (no) Tris-hydroxymethyl-lavere-alkanestere som fettimitasjoner.
NO900648D0 (no) Seksjonsdelt strekkramme for malerlerret.
FI941146A0 (fi) Iskulaite
GB2287953B (en) High stability, organic tanning processes
FI901546A0 (fi) Kompositioner innehaollande 2-tiocyanometyltiobensotiazol foer anvaendning i industriella mikrobiocider.
BR9407024A (pt) Processo para a preparação de 4,6-diamino-5-cianopirimidinas substituídas
NO902334D0 (no) Fremgangsmaate ved fremstilling av beholdere.
BR9007862A (pt) Tinturas de benzoxazina
NO931865D0 (no) Anordning ved kjernebor
NO950223D0 (no) Fremgangsmåte for fremstilling av kjeks, samt slik kjeks
NO880100D0 (no) Fremgangsmaate ved utskiftning av anoder.
DE69002476D1 (de) Kationisches elektro-abscheidbares anstrichmittel.
ES1025981Y (es) Director-extractor de gases.
FI932968L (fi) Menetelmä 2-n-butyyli-2-etyyli-1,3-propaanidiolin valmistamiseksi
FR2706142B1 (fr) Rasoir de sûreté.
BR9408162A (pt) Derivados de ácido 2,3,5,6-tetrafluorbenzóico
BR9305542A (pt) Processo para a preparação de 5-alcóxi-2,4-dinitro-alquilbenzenos
AU7695094A (en) Alkyl-1-alkyl-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxylat es as anti-rheumatic agents
NO881867L (no) Fremgangsmaate ved ensilering.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application